5 research outputs found
Integrated Flight and Propulsion Control for Novel Rotorcraft
Distributed Electric Propulsion (DEP) has increased the design space for aerospace vehicles, especially those categorized as eVTOL (Electric Vertical Take-Off and Landing). This new class of vehicles not only looks different from the typical airplane or helicopter, but functions differently as well. A robust understanding of how the vehicle is controlled in both nominal and off-nominal modes will frame the approach to certification for private and commercial VTOL aircraft.
Embry-Riddle Aeronautical University’s Eagle Flight Research Center (EFRC) is researching how the various methods of DEP thrust control apply to larger eVTOL vehicle operation. Researchers will utilize a mixture of flight dynamic simulation and physical testing in collaboration with FAA experts in rotorcraft handling qualities certification. Outcomes of the research include the characterization of various DEP thrust and moment control methods and how this maps to certifiable vehicle-level attributes like handling qualities in nominal and degraded flight modes. A prototype will be built and tested showing the ability of a quad-rotor vehicle to continue flight after the loss of thrust by failure of one rotor.
It is anticipated that a better understanding of the DEP units will help inform the process of certification for the emerging market of urban air mobility vehicles. The data obtained from testing will be utilized to define the possible performance parameters, which will aid in developing appropriate means of compliance for advanced fly-by-wire N-rotor eVTOL vehicles
The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients
It is well established that several inflammatory-type conditions, such as arthritis, diabetes, cardiovascular disease, and irritable bowel disease exist comorbidly and at an increased incidence in patients with psoriasis. Psoriasis and other associated diseases are thought to share common inflammatory pathways. Conditions such as these, with similar pathogenic mechanisms involving cytokine dysregulation, are referred to as immune-mediated inflammatory diseases (IMIDs). Considerable evidence for the genetic basis of cormobidities in psoriasis exists. The WHO has reported that the occurrence of chronic diseases, including IMIDs, are a rising global burden. In addition, conditions linked with psoriasis have been associated with increasing rates of considerable morbidity and mortality. The presence of comorbid conditions in psoriasis patients has important implications for clinical management. QoL, direct health care expenditures and pharmacokinetics of concomitant therapies are impacted by the presence of comorbid conditions. For example, methotrexate is contraindicated in hepatic impairment, while patients on ciclosporin should be monitored for kidney function. In addition, some agents, such as beta blockers, lithium, synthetic antimalarial drugs, NSAIDs and tetracycline antibiotics, have been implicated in the initiation or exacerbation of psoriasis. Consequently, collaboration between physicians in different specialties is essential to ensuring that psoriasis treatment benefits the patient without exacerbating associated conditions
RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation
Chikungunya virus (CHIKV) is an arthritogenic alphavirus causing epidemics of acute and chronic arthritic disease. Herein we describe a comprehensive RNA-Seq analysis of feet and lymph nodes at peak viraemia (day 2 post infection), acute arthritis (day 7) and chronic disease (day 30) in the CHIKV adult wild-type mouse model. Genes previously shown to be up-regulated in CHIKV patients were also up-regulated in the mouse model. CHIKV sequence information was also obtained with up to ≈8% of the reads mapping to the viral genome; however, no adaptive viral genome changes were apparent. Although day 2, 7 and 30 represent distinct stages of infection and disease, there was a pronounced overlap in up-regulated host genes and pathways. Type I interferon response genes (IRGs) represented up to ≈50% of up-regulated genes, even after loss of type I interferon induction on days 7 and 30. Bioinformatic analyses suggested a number of interferon response factors were primarily responsible for maintaining type I IRG induction. A group of genes prominent in the RNA-Seq analysis and hitherto unexplored in viral arthropathies were granzymes A, B and K. Granzyme Aand to a lesser extent granzyme K, but not granzyme B, mice showed a pronounced reduction in foot swelling and arthritis, with analysis of granzyme Amice showing no reductions in viral loads but reduced NK and T cell infiltrates post CHIKV infection. Treatment with Serpinb6b, a granzyme A inhibitor, also reduced arthritic inflammation in wild-type mice. In non-human primates circulating granzyme A levels were elevated after CHIKV infection, with the increase correlating with viral load. Elevated granzyme A levels were also seen in a small cohort of human CHIKV patients. Taken together these results suggest granzyme A is an important driver of arthritic inflammation and a potential target for therapy. Trial Registration: ClinicalTrials.gov NCT0028129